Driving eligibility stays after multispot PRP laser treatment

Multispot Panretinal Photocoagulation Spares Visual Fields Required For Driving Eligibility

Valon Lasers is pleased to report that Valon Multispot Laser panretinal photocoagulation (PRP) in proliferative diabetic retinopathy spares visual fields required for driving eligibility according to a study from University College London Institute of Ophthalmology, U.K.

Recently published study by Professor Michel Michaelides et al. assessed the effect of Multispot laser PRP on retinal sensitivity and visual fields required for driving eligibility in 43 laser naïve diabetic retinopathy patients that required bilateral PRP. 41 of 43 (95%) patients passed the Esterman visual-field testing in accordance with U.K. driving standards. 38 of the 41 patients completed the study, and at six-month follow-up, 35 of 38 patients (92%) passed. The study was conducted with Valon TT Multispot Laser.

“ With the increasing worldwide use of multispot laser for application of PRP, ophthalmologists must be able to advice patients accurately on whether PRP for diabetic retinopathy may jeopardize their entitlement to a driving license. This study identified no loss of driving eligibility on the basis of visual field criteria in almost all patients”, state the researchers.

“We have had the privilege to follow this study at a near proximity. With their prospective study, Professor Michaelides and colleagues have given ophthalmologists worldwide a better baseline for patient consultation. This is also very good news for patients, who, due to regular screenings often receive diagnosis and treatment at an earlier stage of the condition”, says Valon Lasers’ CEO, Mr Juha Viherkoski.

The study was published online on April 14, 2016 by JAMA Ophthalmol http://archopht.jamanetwork.com/article.aspx?articleid=2512093&resultClick=3#ResultsFor more
information on Valon Multispot Lasers and Valon Lasers, please visit www.valon.fi

Finnish Valon Lasers, founded in 2011, develops and produces solutions for the ophthalmic markets. Valon 532 nm pattern scanning photocoagulators, Valon TT and Valon 5G are used in over 300 clinics worldwide.

Valon Lasers Oy
Teknobulevardi 3-5, 01530 Vantaa, Finland
Tel: +358 50 434 5421, email: info@valon.fi

Media contact: Mira Kekarainen
tel: +358 40 522 9406, email: mira.kekarainen@valon.fi

This release was published on openPR.